DLGAP5 Antikörper (N-Term)
Kurzübersicht für DLGAP5 Antikörper (N-Term) (ABIN630974)
Target
Alle DLGAP5 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- N-Term
-
Spezifität
- DLG7 antibody was raised against the N terminal Of Dlg7
-
Aufreinigung
- Affinity purified
-
Immunogen
- DLG7 antibody was raised using the N terminal Of Dlg7 corresponding to a region with amino acids EYERNRHFGLKDVNIPTLEGRILVELDETSQELVPEKTNVKPRAMKTILG
-
-
-
-
Applikationshinweise
-
WB: 1 µg/mL
Optimal conditions should be determined by the investigator. -
Kommentare
-
DLG7 Blocking Peptide, (ABIN938206), is also available for use as a blocking control in assays to test for specificity of this DLG7 antibody
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of DLG7 antibody in PBS
-
Konzentration
- Lot specific
-
Buffer
- PBS
-
Handhabung
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- DLGAP5 (Discs, Large (Drosophila) Homolog-Associated Protein 5 (DLGAP5))
-
Andere Bezeichnung
- DLG7
-
Hintergrund
- DLG7 is a potential cell cycle regulator that may play a role in carcinogenesis of cancer cells. It is a mitotic phosphoprotein regulated by the ubiquitin-proteasome pathway. DLG7 is the key regulator of adherens junction integrity and differentiation that may be involved in CDH1-mediated adhesion and signaling in epithelial cells.
-
Molekulargewicht
- 95 kDa (MW of target protein)
-
Pathways
- M Phase
Target
-